ArticleClinical and vaccine immunology : CVI2012
Protection against lethal leptospirosis after vaccination with LipL32 coupled or coadministered with the B subunit of Escherichia coli heat-labile enterotoxin.
Article in Clinical and vaccine immunology : CVI, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Advances in the development of a vaccine for the prevention of human leptospirosis: a review.Revista do Instituto de Medicina Tropical de Sao Paulo · 2026Review
- Genetic Analysis of LigA, LipL32, Loa22, and OmpL1 Antigens from Leptospira spp. Sejroe Serogroup: How Close We Are To a Vaccine Against Bovine Leptospirosis?Current microbiology · 2023Article
- A Recombinant Chimera Vaccine Composed of LTB andVaccines · 2023Article
- Challenges and Strategies for Developing Recombinant Vaccines against Leptospirosis: Role of Expression Platforms and Adjuvants in Achieving Protective Efficacy.Pathogens (Basel, Switzerland) · 2023Review
- In Silico Approaches for the Identification of Aptamer Binding Interactions toTropical medicine and infectious disease · 2023Article
- Vaccination WithFrontiers in cellular and infection microbiology · 2022Article
- Evaluation of Immunogenicity and Efficacy ofVaccines · 2021Article
- Vaccine potential of LenA and LcpA proteins ofIranian journal of microbiology · 2019Article
- Th2-biased immune response and agglutinating antibodies generation by a chimeric protein comprising OmpC epitope (323-336) of Aeromonas hydrophila and LTB.Immunologic research · 2018Article
- Evaluation of Lsa46 and Lsa77 Leptospiral Proteins for Their Immunoprotective Activities in Hamster Model of Leptospirosis.BioMed research international · 2018Article
- Advances & challenges in leptospiral vaccine development.The Indian journal of medical research · 2018Review
- Molecular characterization of the recombinant protein RmLTI-BmCG-LTB: Protective immunity against Rhipicephalus (Boophilus) microplus.PloS one · 2018Article
- Reverse Vaccinology: An Approach for Identifying Leptospiral Vaccine Candidates.International journal of molecular sciences · 2017Review
- Spirochetal Lipoproteins and Immune Evasion.Frontiers in immunology · 2017Review
- Discovery of Novel Leptospirosis Vaccine Candidates Using Reverse and Structural Vaccinology.Frontiers in immunology · 2017Article
- Immunity to Avian Leukosis Virus: Where Are We Now and What Should We Do?Frontiers in immunology · 2016Review
- Evaluation of cell binding activities of Leptospira ECM adhesins.PLoS neglected tropical diseases · 2015Article
- Current immunological and molecular tools for leptospirosis: diagnostics, vaccine design, and biomarkers for predicting severity.Annals of clinical microbiology and antimicrobials · 2015Review
- Evaluation of the Leptospira interrogans Outer Membrane Protein OmpL37 as a Vaccine Candidate.PloS one · 2015Article
- Immunogenicity of a novel enhanced consensus DNA vaccine encoding the leptospiral protein LipL45.Human vaccines & immunotherapeutics · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Leptospirosis, a worldwide zoonosis, lacks an effective, safe, and cross-protective vaccine. LipL32, the most abundant, immunogenic, and conserved surface lipoprotein present in all pathogenic species of Leptospira, is a promising antigen candidate for a recombinant vaccine. However, several studies have reported a lack of protection when this protein is used as a subunit vaccine. In an attempt to enhance the immune response, we used LipL32 coupled to or coadministered with the B subunit of the Escherichia coli heat-labile enterotoxin (LTB) in a hamster model of leptospirosis. After homologous challenge with 5× the 50% lethal dose (LD(50)) of Leptospira interrogans, animals vaccinated with LipL32 coadministered with LTB and LTB::LipL32 had significantly higher survival rates (P < 0.05) than animals from the control group. This is the first report of a protective immune response afforded by a subunit vaccine using LipL32 and represents an important contribution toward the development of improved leptospirosis vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.